Sarepta Therapeutics Inc (NASDAQ:SRPT) – Investment analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz expects that the biotechnology company will post earnings per share of ($0.45) for the quarter. Leerink Swann currently has a “Outperform” rating and a $77.00 price target on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2018 earnings at ($1.21) EPS and FY2019 earnings at $0.51 EPS.
A number of other analysts also recently weighed in on the company. Barclays restated a “hold” rating and issued a $55.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 23rd. Royal Bank of Canada started coverage on Sarepta Therapeutics in a research report on Monday, January 22nd. They set an “outperform” rating on the stock. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 9th. Finally, Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus price target of $64.65.
Sarepta Therapeutics (SRPT) traded down $0.44 during trading hours on Monday, hitting $65.10. The stock had a trading volume of 849,044 shares, compared to its average volume of 1,700,000. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $68.90. The firm has a market capitalization of $4,210.00, a price-to-earnings ratio of -31.91 and a beta of 1.37.
In other news, CEO Douglas S. Ingram purchased 38,138 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the sale, the director now owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.
A number of large investors have recently made changes to their positions in SRPT. Jennison Associates LLC increased its stake in Sarepta Therapeutics by 103.9% during the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after acquiring an additional 582,894 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth about $26,011,000. Voya Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after buying an additional 548,826 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Sarepta Therapeutics by 3,599.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after buying an additional 519,650 shares during the period. Finally, HealthCor Management L.P. boosted its position in shares of Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after buying an additional 481,890 shares during the period. Institutional investors own 81.98% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.45) Per Share (NASDAQ:SRPT)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/01/sarepta-therapeutics-inc-expected-to-earn-q1-2018-earnings-of-0-45-per-share-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.